The takeaway
Lexeo Therapeutics, Inc. Common Stock shows a pronounced seasonal pattern over 3 years of data — strongest in March (+26.9%) and softest in February (−30.7%).
Right now
In July, the stock has fallen 50% of years, averaging −3.8%, roughly 5.9 pts behind the S&P 500.
The full picture
Lexeo Therapeutics, Inc. Common Stock's most dependable month has been March, higher in 2 of 2 years; February has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | — | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in March (+25.8 pts); it has trailed the market most in February (−30.5 pts).
“vs S&P” is Lexeo Therapeutics, Inc. Common Stock’s average for a month minus the S&P 500’s average for that same month — isolating Lexeo Therapeutics, Inc. Common Stock’s own seasonal edge from broad market drift.
Reality check
Not enough recent March history to say whether the pattern still holds.
Figures are the typical (median) March return and how often it rose — the last 2 years versus the last 3(the heatmap’s default window). This verdict stays anchored to that 3-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
The seasonal story is really one month's story — March. It has closed higher in all 2 Marches, a concentration the rest of the calendar can't touch.
The strength looks broad-based rather than freakish: its average (+26.9%) and median (+26.9%) sit close together, so no single blow-out year is flattering the figure. That reliability comes with real swings, mind — even March ranges by 21.4% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — March has outpaced the S&P 500 by +25.8 points on average. Few peers keep such company in March — the typical stock clears it just 56% of the time.
Only November comes anywhere near it for reliability. At the other end of the calendar, February has been the soft spot — the weakest of 6 months that average a loss (−30.7%), and the edge isn't year-round — the stock has trailed the S&P 500 in February, December, and July. Its roughest month on record was a −48.5% February in 2025 — a reminder of how hard even a seasonal name can fall.
For a stock this dependable in March, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on. With a short 3-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (March), its worst (February), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2023 its best month (March, +26.9%) has run well ahead of its worst (February, −30.7%) — the heatmap above shows how steady that gap has been year to year.
March has been the strongest, averaging +26.9% and closing higher in all 2 years on record since 2023.
It's the weakest, averaging −30.7% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade